Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.

@article{Legendre2013TerminalCI,
  title={Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.},
  author={Christophe M Legendre and Christoph Licht and Petra Muus and Laurence A Greenbaum and Suresh Babu and Camille L. Bedrosian and Clifford Bingham and David J. Cohen and Yahsou Delmas and Kathe Douglas and Frank Eitner and Thorsten Feldkamp and Denis Fouque and Richard R. Furman and Ola Gaber and Maria Herthelius and Maryvonne Hourmant and Diana Karpman and Yvon Lebranchu and Christophe Mariat and Jan Menne and Bruno Moulin and Jens Nuernberger and Mei Ogawa and Giuseppe Remuzzi and Tere Richard and R{\'e}becca Sberro-Soussan and Beatrice Severino and Neil S Sheerin and Antonella Trivelli and Lothar Bernd Zimmerhackl and Timothy H. J. Goodship and Chantal Loirat},
  journal={The New England journal of medicine},
  year={2013},
  volume={368 23},
  pages={2169-81}
}
BACKGROUND Atypical hemolytic-uremic syndrome is a genetic, life-threatening, chronic disease of complement-mediated thrombotic microangiopathy. Plasma exchange or infusion may transiently maintain normal levels of hematologic measures but does not treat the underlying systemic disease. METHODS We conducted two prospective phase 2 trials in which patients with atypical hemolytic-uremic syndrome who were 12 years of age or older received eculizumab for 26 weeks and during long-term extension… CONTINUE READING
Highly Influential
This paper has highly influenced 23 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 341 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 35 references

Eculizumab in the treatment of aHUS in infants

  • G Ariceta, B Arriyabalaga, M Aguirre
  • Am J Kidney Dis
  • 2012

Similar Papers

Loading similar papers…